BioPharmX Corp fka BPMX

[Whos_Who]

On September 15, 2016, BioPharmX Corporation (“Company”) received a notice from the New York Stock Exchange Market (“NYSE MKT”) that NYSE Regulation has reviewed the Company’s compliance plan and determined to accept the plan and grant a plan period through January 20, 2018. NYSE Regulation staff will review the Company periodically for compliance with the initiatives outlined in the plan. If the Company is not in compliance with the continued listing standards by January 20, 2018, or if the Company does not make progress consistent with the plan during the plan period, NYSE Regulation staff will initiate delisting proceedings as appropriate. The Company may appeal a staff delisting determination in accordance with Section 1010 and Part 12 of the NYSE MKT Company Guide.

http://ih.advfn.com/p.php?pid=nmona&article=72472972&symbol=BPMX